New Member Brings Broad Rheumatology Expertise
BOULDER, Colo.--(BUSINESS WIRE)--May 8, 2007--Array BioPharma Inc.
(NASDAQ: ARRY) today announced the appointment of Jonathan Kay, M.D.,
to its Scientific Advisory Board. Dr. Kay will work with the Array
team to facilitate the development of its inflammation portfolio.
"Dr. Kay's vast experience with novel therapies in the clinic, as
well as his strong research interest to improve clinical practice in
rheumatology, will be a valuable scientific addition to Array," said
Kevin Koch, Ph.D., President and Chief Scientific Officer, Array
BioPharma. "As a leader in the field of rheumatology he will
contribute valuable knowledge and expertise as we move our
inflammation programs forward in clinical development."
"It is a great opportunity to participate in developing Array's
promising drug pipeline," said Dr. Kay. "I look forward to helping to
guide the development of Array's breakthrough treatments for
inflammation as a member of the Scientific Advisory Board."
Background - Jonathan Kay, M.D.
Dr. Kay is the Director of Clinical Trials in the MGH Rheumatology
Unit and an Associate Clinical Professor of Medicine at Harvard. Dr.
Kay has been a principal investigator on over 30 clinical trials of
novel therapies for rheumatoid arthritis, gout and osteoarthritis. He
is the author of more than 50 publications and book chapters and is
internationally recognized as a leader improving the clinical practice
of rheumatology.
Dr. Kay received his undergraduate degree from Harvard University
and his medical degree from the University of California School of
Medicine in San Francisco. He completed training in Internal Medicine
at the Hospital of the University of Pennsylvania and fellowships in
Rheumatology and Immunology at the Brigham and Women's Hospital and
Harvard Medical School in Boston.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small
molecule drugs to treat life-threatening and debilitating diseases.
Our proprietary drug development pipeline is focused on the treatment
of cancer and inflammatory disease and includes clinical candidates
that are designed to regulate therapeutically important targets. In
addition, leading pharmaceutical and biotechnology companies
collaborate with Array to discover and develop drug candidates across
a broad range of therapeutic areas. For more information on Array,
please go to www.arraybiopharma.com.
Forward-Looking Statement:
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements involve significant risks and uncertainties, including
those discussed in our annual report filed on form 10-K for the year
ended June 30, 2006, our quarterly report on Form 10-Q for the quarter
ended March 31, 2007, and in other reports filed by Array with the
Securities and Exchange Commission. Because these statements reflect
our current expectations concerning future events, our actual results
could differ materially from those anticipated in these
forward-looking statements as a result of many factors. These factors
include, but are not limited to, our ability to continue to fund and
successfully progress internal research efforts and to create
effective, commercially viable drugs, our ability to achieve and
maintain profitability, the extent to which the pharmaceutical and
biotechnology industries are willing to in-license drug candidates for
their product pipelines and to collaborate with and fund third parties
on their drug discovery activities, our ability to out-license our
proprietary candidates on favorable terms, risks associated with our
dependence on our collaborators for the clinical development and
commercialization of our out-licensed drug candidates, the ability of
our collaborators and of Array to meet objectives tied to milestones
and royalties, and our ability to attract and retain experienced
scientists and management. We are providing this information as of May
8, 2007. We undertake no duty to update any forward-looking statements
to reflect the occurrence of events or circumstances after the date of
such statements or of anticipated or unanticipated events that alter
any assumptions underlying such statements.
CONTACT: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
SOURCE: Array BioPharma Inc.
